ReviewSmart molecules : open access2026
Advances in research on layered double hydroxides for biomedical applications.
Review in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Layered double hydroxides (LDHs), as a typical class of two-dimensional layered nanomaterials, have attracted extensive attention in biomedical fields due to their unique layered structure, tunable chemical composition, good biocompatibility, ease of surface functionalization, and efficient drug loading and controlled release capabilities. This review systematically summarizes recent advances in the research on LDHs for biomedical applications, focusing on their potential in drug delivery, bioimaging, and other disease treatments. Studies demonstrate that LDHs function as efficient carriers for a range of bioactive molecules, including anticancer drugs, nucleic acids, and proteins. Targeted and controlled release is enabled through mechanisms like pH responsiveness and ion exchange. Their favorable biodegradability and low cytotoxicity provide a safety basis for in vivo applications. Moreover, LDHs exhibit remarkable advantages in photothermal therapy, synergistic therapy, and the construction of multifunctional theranostic platforms. Despite significant progresses, challenges remain regarding long-term biosafety, scalable fabrication, and clinical translation. In the future, through rational design and multifunctional integration, LDHs are expected to become key components in next-generation intelligent nanotheranostic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.